保齡寶(002286.SZ):倍健食品擬將上海曼巴30%股權轉讓給上海瑞希康
格隆匯2月8日丨保齡寶(002286.SZ)公佈,公司全資子公司山東保齡寶倍健食品有限公司(“倍健食品”)擬將所持有的上海曼巴蔓芭健康科技有限公司(“上海曼巴”)30%股權(對應認繳出資人民幣1200萬元,實繳出資人民幣600萬元)轉讓給上海瑞希康醫學技術有限公司(“上海瑞希康”),轉讓金額為人民幣480萬元。
此次交易前,倍健食品持有上海曼巴30%股權(對應認繳出資人民幣1200萬元,實繳出資人民幣600萬元),此次交易完成後,倍健食品將不再持有上海曼巴股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.